NCT03808922

        inclusion criteria:

          1. at the time of randomization, requires supplemental oxygen ≥2 lpm due to hypoxemia.

          2. immunocompromised, as defined by one or more of the following:

               -  received an autologous or allogeneic hematopoietic stem cell transplantation
                  (hsct) at any time in the past

               -  received a solid organ transplant at any time in the past

               -  has been or is currently being treated with chemotherapy for hematologic
                  malignancies (e.g., leukemia, myeloma, lymphoma) and/or solid tumor malignancies
                  (e.g., lung, breast, brain cancer) at any time in the past

               -  has an immunodeficiency due to congenital abnormality (only applicable to
                  subjects age < 18 years old) or pre-term birth (only applicable to subjects age ≤
                  2 years old)

          3. has, within 3 days prior to randomization, a confirmed lrti with a sialic acid
             dependent respiratory virus

          4. if female, subject must meet one of the following conditions:

               -  not be of childbearing potential or

               -  be of childbearing potential and have a negative urine/serum pregnancy test and
                  agrees to practice an acceptable method of contraception

          5. non-vasectomized males are required to practice effective birth control methods

          6. capable of understanding and complying with procedures as outlined in the protocol

          7. provides signed informed consent prior to the initiation of any screening or
             study-specific procedures

        for covid-19 sub study:

          1. be ≥18 years of age

          2. provide adequate medical history to permit accurate stratification (but health status
             may be healthy, high-risk conditions, or immunocompromised).

          3. prior to sars cov 2 infection, has the ability to carry out self-care activities of
             daily living (basic adl)

          4. have lower respiratory tract infection (lrti) confirmed by ct imaging, with or without
             contrast, to involve at least 2 lobes of the lung.

          5. has laboratory-confirmation of the presence of sars cov 2 in the respiratory tract by
             at least one of the following samples

          6. satisfy inclusion criteria #1, 4, 5, 6, 7 of the main study

        exclusion criteria:

          1. subjects may not be on hospice care or, in the opinion of the investigator, have a low
             chance of survival during the first 10 days of treatment

          2. subjects with alanine aminotransferase (alt), aspartate aminotransferase (ast), or
             alkaline phosphatase (alp) ≥3x uln and total bilirubin (tbili) ≥2x uln note: subjects
             with alt/ast/alp ≥ 3x uln and tb ≥2x uln that have been chronically stable (for >1
             year on more than one assessments) due to known liver pathology including malignancy
             (primary or metastasis), chronic medications, transplantation, or chronic infection
             will not be excluded

          3. female subjects breastfeeding or planning to breastfeed at any time through 30 days
             after the last dose of study drug

          4. subjects taking any other investigational drug used to treat pulmonary infection.

          5. psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion
             of the principal investigator, would affect subject safety and/or compliance

          6. subjects with known hypersensitivity to das181 and/or any of its components

          7. subjects with severe sepsis due to either their baseline sad-rv infection or a
             concurrent viral, bacterial, or fungal infection and meet at least one of the
             following criteria:

               -  has evidence of vital organ failure outside of the lung (e.g., liver, kidney)

               -  requires vasopressors to maintain blood pressure

        for covid-19 sub study:

          1. subjects requiring invasive mechanical, bi-pap or cpap ventilation at randomization.

          2. subjects receiving any other investigational or empiric treatment for sars-2-cov
             (either as part of a clinical trial or under emergency approval (approved agents for
             the management of symptoms, e.g., fever, are permitted).

          3. subjects who are known hiv-positive (and not undetectable at most recent hiv rna
             assessment)

          4. subjects who are currently taking immunomodulating biologics (e.g, interferons,
             interleukin)

          5. subjects with severe sepsis due to either their sars-cov-2 infection or a concurrent
             viral, bacterial, or fungal infection and meeting at least one of the following
             criteria:

               -  have evidence of vital organ failure outside of the lung (e.g., liver, kidney)

               -  require vasopressors to maintain blood pressure

          6. subjects meeting exclusion criteria #2, 3, 5 and 6 of the main study
      


NCT04280705

        inclusion criteria:

          1. admitted to a hospital with symptoms suggestive of covid-19 infection.

          2. subject (or legally authorized representative) provides informed consent prior to
             initiation of any study procedures.

          3. subject (or legally authorized representative) understands and agrees to comply with
             planned study procedures.

          4. male or non-pregnant female adult > / = 18 years of age at time of enrollment.

          5. has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain
             reaction (pcr) or other commercial or public health assay in any specimen, as
             documented by either or the following:

               -  pcr positive in sample collected < 72 hours prior to randomization; or

               -  pcr positive in sample collected >/= 72 hours prior to randomization, documented
                  inability to obtain a repeat sample (e.g. due to lack of testing supplies,
                  limited testing capacity, results taking >24 hours, etc.) and progressive disease
                  suggestive of ongoing sars-cov-2 infection.

          6. illness of any duration, and at least one of the following:

               -  radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or

               -  spo2 < / = 94% on room air, or

               -  requiring supplemental oxygen, or

               -  requiring mechanical ventilation.

          7. women of childbearing potential must agree to either abstinence or use at least one
             primary form of contraception not including hormonal contraception from the time of
             screening through day 29.

          8. agrees to not participate in another clinical trial for the treatment of covid-19 or
             sars-cov-2 through day 29.

        exclusion criteria:

          1. alanine transaminase (alt) or aspartate transaminase (ast) > 5 times the upper limit
             of normal.

          2. estimated glomerular filtration rate (egfr) < 30 ml/min (including patients receiving
             hemodialysis or hemofiltration).

          3. pregnancy or breast feeding.

          4. anticipated discharge from the hospital or transfer to another hospital which is not a
             study site within 72 hours.

          5. allergy to any study medication.
      


NCT04292730

        key inclusion criteria:

          -  willing and able to provide written informed consent prior to performing study
             procedures (participants ≥ 18 years of age) or assent (participants ≥ 12 and < 18
             years of age) prior to performing study procedures. for participants ≥ 12 and < 18
             years of age, a parent or legal guardian willing and able to provide written informed
             consent prior to performing study procedures

          -  severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by
             polymerase chain reaction (pcr) test ≤ 4 days before randomization

          -  currently hospitalized and requiring medical care for covid-19

          -  peripheral capillary oxygen saturation (spo2) > 94% on room air at screening

          -  radiographic evidence of pulmonary infiltrates

        key exclusion criteria:

          -  participation in any other clinical trial of an experimental treatment for covid-19

          -  concurrent treatment with other agents with actual or possible direct acting antiviral
             activity against sars-cov-2 < 24 hours prior to study drug dosing

          -  requiring mechanical ventilation at screening

          -  alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 x upper limit
             of normal (uln)

          -  creatinine clearance < 50 ml/min using the cockcroft-gault formula for participants ≥
             18 years of age {cockcroft 1976} and schwartz formula for participants < 18 years of
             age

        note: other protocol defined inclusion/exclusion criteria may apply.
      


NCT04292899

        key inclusion criteria:

          -  willing and able to provide written informed consent, or with a legal representative
             who can provide informed consent, or enrolled under international conference on
             harmonization (ich) e6(r2) 4.8.15 emergency use provisions as deemed necessary by the
             investigator (age ≥18), or willing and able to provide assent (age ≥12 to <18, where
             locally and nationally approved) prior to performing study procedures

          -  aged ≥ 18 years (at all sites), or aged ≥ 12 and < 18 years of age weighing ≥ 40 kg
             (where permitted according to local law and approved nationally and by the relevant
             institutional review board [irb] or independent ethics committee [iec])

          -  severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by
             polymerase chain reaction (pcr) test ≤ 4 days before randomization

          -  currently hospitalized

          -  peripheral capillary oxygen saturation (spo2) ≤ 94% or requiring supplemental oxygen
             at screening

        key exclusion criteria:

          -  participation in any other clinical trial of an experimental treatment for covid-19

          -  concurrent treatment with other agents with actual or possible direct acting antiviral
             activity against sars-cov-2 is prohibited < 24 hours prior to study drug dosing

          -  evidence of multiorgan failure

          -  mechanically ventilated (including v-v ecmo) ≥ 5 days, or any duration of v-a ecmo.

          -  alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 x upper limit
             of normal (uln)

          -  creatinine clearance < 50 ml/min using the cockcroft-gault formula for participants ≥
             18 years of age {cockcroft 1976} and schwartz formula for participants < 18 years of
             age

        note: other protocol defined inclusion/exclusion criteria may apply.
      


NCT04308668

        inclusion criteria:

          -  provision of informed consent

          -  exposure to a covid19 case within 4 days as either a healthcare worker or household
             contact, or

          -  symptomatic covid19 case with confirmed diagnosis within 4 days of symptom onset or
             symptomatic healthcare worker with known covid19 contact and within 4 days of symptom
             onset;

        exclusion criteria:

          -  current hospitalization

          -  allergy to hydroxychloroquine

          -  retinal eye disease

          -  known glucose-6 phosphate dehydrogenase (g-6-pd) deficiency

          -  known chronic kidney disease, stage 4 or 5 or receiving dialysis

          -  weight < 40 kg

          -  known porphyria

          -  current use of: hydroxychloroquine or cardiac medicines of: flecainide, tambocor;
             amiodarone, cordarone, pacerone; digoxin or digox, digitek, lanoxin; procainamide or
             procan, procanbid, propafenone, rythmal)
      


NCT04315298

        key inclusion criteria:

          -  laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction
             (pcr), result from any specimen (or other commercial or public health assay) within 2
             weeks prior to randomization and no alternative explanation for current clinical
             condition

          -  hospitalized with illness of any duration with evidence of pneumonia and severe
             disease, critical disease, multi-system organ dysfunction or immunocompromised at
             baseline

          -  ability to provide informed consent signed by study patient or legally acceptable
             representative

          -  willingness and ability to comply with study-related procedures/assessments

        key exclusion criteria:

          -  in the opinion of the investigator, not expected to survive for more than 48 hours
             from screening

          -  presence of any of the following abnormal laboratory values at screening: absolute
             neutrophil count (anc) less than 2000 mm3, aspartate aminotransferase (ast) or alanine
             aminotransferase (alt) greater than 5 x upper limit of normal (uln), platelets <50,000
             per mm3

          -  treatment with anti-il 6, anti-il-6r antagonists, or with janus kinase inhibitors
             (jaki) in the past 30 days or plans to receive during the study period

          -  current treatment with the simultaneous combination of leflunomide and methotrexate

          -  known active tuberculosis (tb), history of incompletely treated tb, suspected or known
             extrapulmonary tb, suspected or known systemic bacterial or fungal infections

          -  patients who have received immunosuppressive antibody therapy within the past 5
             months, including intravenous immunoglobulin or plans to receive during the study
             period

          -  participation in a double-blind clinical research study evaluating an investigational
             product (ip) or therapy within 3 months and less than 5 half-lives of ip prior to the
             screening visit (the use of remdesivir, hydroxychloroquine, or other treatments being
             used for covid-19 treatments in the context of an open-label study or compassionate
             use protocol is permitted)

          -  any physical examination findings, and/or history of any illness, concomitant
             medications or recent live vaccines that, in the opinion of the study investigator,
             might confound the results of the study or pose an additional risk to the patient by
             their participation in the study

          -  known systemic hypersensitivity to sarilumab or the excipients of the drug product

        note: other protocol defined inclusion / exclusion criteria may apply
      


NCT04317040

        inclusion criteria:

          1. should be at least 18 years of age,

          2. male or female,

          3. diagnosed with covid-19 and confirmed sars-cov-2 viral infection.

          4. able to sign the consent form.

          5. severe covid-19 (appendix a), or niaid 8-point ordinal score 3 to 4 (requiring
             non-invasive ventilation or oxygen, a spo2 </= 94% or tachypnea (respiratory rate >/=
             24 breaths/min), appendix b).

        exclusion criteria:

          1. patients with covid 19 in critical condition or ards (appendix a) or niaid 8-point
             ordinal score 2 (hospitalized, on invasive mechanical ventilation or extracorporeal
             membrane oxygenation (ecmo)).

          2. patients with bacterial / fungal infections.

          3. patients who are pregnant, breastfeeding, or have a positive pregnancy test result
             before enrollment.

          4. severe liver damage (child-pugh score ≥ c, ast> 5 times the upper limit).

          5. patients with known severe renal impairment (creatinine clearance ≤ 30 ml / min) or
             patients receiving continuous renal replacement therapy, hemodialysis, or peritoneal
             dialysis.

          6. the investigator believes that participating in the trial is not in the best interests
             of the patient, or the investigator considers unsuitable for enrollment (such as
             unpredictable risks or subject compliance issues).
      


NCT04318444

        inclusion criteria:

          -  household contact of index case: currently residing in the same household as an
             individual evaluated at nyp via outpatient, emergency department (ed), or inpatient
             services who (1) test positive for covid-19, or (2) are defined as suspected cases, or
             persons under investigations (pui), by the treating physician.

          -  willing to take study drug as directed for 5 days.

        exclusion criteria:

          -  age <18 years old

          -  suspected or confirmed current covid-19, defined as: (1) temperature > 38 celsius; (2)
             cough; (3) shortness of breath; (4) sore throat; or, if available (not required), (5)
             positive confirmatory testing for covid-19

          -  suspected or confirmed convalescent covid-19, defined as any of the above symptoms
             within the prior 4 weeks.

          -  inability to take medications orally

          -  inability to provide written consent

          -  known sensitivity/allergy to hydroxychloroquine

          -  current use of hydroxychloroquine for another indication

          -  pregnancy

          -  prior diagnosis of retinopathy

          -  prior diagnosis of glucose-6-phosphate dehydrogenase (g6pd) deficiency

          -  major comorbidities increasing risk of study drug including: i. hematologic
             malignancy, ii. advanced (stage 4-5) chronic kidney disease or dialysis therapy, iii.
             known history of ventricular arrhythmias, iv. current use of drugs that prolong the qt
             interval
      


NCT04320615

        inclusion criteria:

          -  hospitalized with covid-19 pneumonia confirmed per who criteria (including a positive
             pcr of any specimen; e.g., respiratory, blood, urine, stool, other bodily fluid) and
             evidenced by chest x-ray or ct scan

          -  spo2 </=93% or pao2/fio2 <300 mmhg

        exclusion criteria:

          -  known severe allergic reactions to tcz or other monoclonal antibodies

          -  active tuberculosis (tb) infection

          -  suspected active bacterial, fungal, viral, or other infection (besides covid-19)

          -  in the opinion of the investigator, progression to death is imminent and inevitable
             within the next 24 hours, irrespective of the provision of treatments

          -  have received oral anti-rejection or immunomodulatory drugs (including tcz) with the
             past 3 months

          -  participating in other drug clinical trials (participation in covid-19 anti-viral
             trials may be permitted if approved by medical monitor)

          -  pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination

          -  treatment with an investigational drug within 5 half-lives or 30 days (whichever is
             longer) of randomization (investigational covid-19 antivirals may be permitted if
             approved by medial monitor)

          -  any serious medical condition or abnormality of clinical laboratory tests that, in the
             investigator's judgment, precludes the patient's safe participation in and completion
             of the study

          -  alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 10 x upper limit
             of normal (uln) detected within 24 hours at screening (per local lab)

          -  absolute neutrophil count (anc) < 1000/ml at screening (per local lab)

          -  platelet count < 50,000/ml at screening (per local lab)
      


NCT04322682

        inclusion criteria:

          1. males and females, at least 40 years of age, capable and willing to provide informed
             consent;

          2. patient must have received a diagnosis of covid-19 infection within the last 24 hours;

          3. outpatient setting (not currently hospitalized or under immediate consideration for
             hospitalization);

          4. patient must possess at least one of the following high-risk criteria: 70 years or
             more of age, diabetes mellitus, uncontrolled hypertension (systolic blood pressure
             ≥150 mm hg), known respiratory disease (including asthma or chronic obstructive
             pulmonary disease), known heart failure, known coronary disease, fever of ≥38.4°c
             within the last 48 hours, dyspnea at the time of presentation, bicytopenia,
             pancytopenia, or the combination of high neutrophil count and low lymphocyte count;

          5. female patient is either not of childbearing potential, defined as postmenopausal for
             at least 1 year or surgically sterile, or is of childbearing potential and practicing
             at least one method of contraception and preferably two complementary forms of
             contraception including a barrier method (e.g. male or female condoms, spermicides,
             sponges, foams, jellies, diaphragm, intrauterine device (iud)) throughout the study
             and for 30 days after study completion;

          6. patient must be able and willing to comply with the requirements of this study
             protocol.

        exclusion criteria:

          1. patient currently hospitalized or under immediate consideration for hospitalization;

          2. patient currently in shock or with hemodynamic instability;

          3. patient with inflammatory bowel disease (crohn's disease or ulcerative colitis),
             chronic diarrhea or malabsorption;

          4. patient with pre-existent progressive neuromuscular disease;

          5. estimated glomerular filtration rate (egfr), using the mdrd equation for all subjects
             being considered for enrollment, with a cut-off of < 30 ml/m in/1.73m2;

          6. patient with a history of cirrhosis, chronic active hepatitis or severe hepatic
             disease;

          7. female patient who is pregnant, or breast-feeding or is considering becoming pregnant
             during the study or for 6 months after the last dose of study medication;

          8. patient currently taking colchicine for other indications (mainly chronic indications
             represented by familial mediterranean fever or gout);

          9. patient with a history of an allergic reaction or significant sensitivity to
             colchicine;

         10. patient undergoing chemotherapy for cancer;

         11. patient is considered by the investigator, for any reason, to be an unsuitable
             candidate for the study.
      


NCT04328012

        inclusion criteria

          1. hospitalized patient

          2. laboratory confirmation of sars-cov-2 infection </= 72 hr prior to randomization

          3. randomization within 72 hr of hospital admission

          4. negative pregnancy test for reproductive age women

          5. patient or lar able to provide informed consent

        exclusion criteria, general (all groups)

          1. end stage renal disease (esrd) not undergoing renal replacement therapy

          2. severe hepatic insufficiency (lfts > 5 times the upper limit of normal or known esld
             or cirrhosis)

          3. nausea/vomiting or aspiration risk precluding oral medications unless can be given by
             gastric tube

          4. use of another sars-cov-2 directed medication empirically or within another clinical
             trial within the prior week

          5. pregnancy or breast feeding

          6. absence of dependable contraception in reproductive age women

          7. inability to obtain or declined informed consent

        exclusion criteria, group specific group 1 (lopinavir/ritonavir)

          1. allergy or intolerance to lopinavir/ritonavir

          2. already taking lopinavir/ritonavir (within 1 month)

          3. known hiv infection and/or taking antiretroviral therapy for another indication

          4. co-administration with certain drugs due to cyp3a interactions if taken in < 24 hr

        group 2 (hydroxychloroquine)

          1. allergy or intolerance to hydroxychloroquine (or chloroquine)

          2. already taking hydroxychloroquine or chloroquine (within 1 month)

          3. recent malaria exposure (within 1 month)

          4. history or current cardiac diseases (heart failure, ventricular arrhythmias, lbbb or
             rbbb, qtc prolongation)

          5. history of retinopathy

          6. severe hypoglycemia

          7. auditory disorders

          8. known g6pd deficiency

          9. porphyria or psoriasis

         10. severe active alcohol use disorder (not in remission)

         11. seizure disorder

         12. co-administration of significant hepatotoxic agents (acetaminophen in standard dosing
             would not be included)

         13. co-administration with certain drugs due to cyp3a interactions if taken in < 24 hr

        group 3 (losartan)

          1. allergy or intolerance to losartan (or ace inhibitors or other arbs)

          2. already taking ace or arb (within 1 month)

          3. hypotension

          4. hyperkalemia (k >/= 5.0 at time of screening or history of hyperkalemia)

          5. blood pressure < 110/70 mm hg or history of hypotension or recent (within 1 month) or
             recurrent syncope

          6. severe renal dysfunction (estimated gfr < 30 ml/min at time of screening or history
             advanced renal disease)

          7. severe volume depletion or acute kidney injury (aki)

          8. known cirrhotic ascites

          9. known severe aortic or mitral valve stenosis

         10. known unstented renal artery stenosis

         11. co-administration with certain drugs due to cyp3a interactions if taken in < 24 hr

        group 4 (standard care [placebo])

        1. none
      


NCT04328467

        inclusion criteria:

        - a healthcare worker at high risk for covid-19 exposure (defined below):

          -  persons primarily working in emergency departments (physicians, nurses, ancillary
             staff, triage personnel)

          -  persons primarily working in intensive care units (physicians, nurses, ancillary
             staff, respiratory therapists)

          -  persons performing aerosol generating procedures (i.e. anesthesiologists, nurse
             anesthetists (crnas)

          -  first responders (i.e. emts, paramedics)

        exclusion criteria:

          -  active covid-19 disease

          -  prior covid-19 disease

          -  current fever, cough, shortness of breath

          -  allergy to chloroquine or hydroxychloroquine

          -  prior retinal eye disease

          -  known chronic kidney disease, stage 4 or 5 or dialysis

          -  known glucose-6 phosphate dehydrogenase (g-6-pd) deficiency

          -  weight <40 kg

          -  prolonged qt syndrome

          -  current use of hydroxychloroquine, chloroquine, or cardiac medicines of flecainide,
             amiodarone, digoxin, procainamide, or propafenone

          -  current use of medications with known significant drug-drug interactions: artemether,
             lumefantrine, mefloquine, tamoxifen, or methotrexate.
      


NCT04328961

        inclusion criteria:

          -  men or women 18 to 80 years of age inclusive, at the time of signing the informed
             consent

          -  willing and able to provide informed consent

          -  had a close contact of a person (index) with known pcr-confirmed sars-cov-2 infection
             or who is currently being assessed for covid-19. close contact defined as:

               1. household contact (i.e., residing with the index case in the 14 days prior to
                  index diagnosis)

               2. medical staff, first responders, or other care persons who cared for the index
                  case without personal protection (mask and gloves)

          -  less than 4 days since last exposure (close contact with a person with sars-cov-2
             infection) to the index case

          -  body weight < 100 kg (self-reported)

          -  access to device and internet for telehealth visits

        exclusion criteria:

          -  known hypersensitivity to hcq or other 4-aminoquinoline compounds

          -  currently hospitalized

          -  symptomatic with subjective fever, cough, or sore throat

          -  current medications exclude concomitant use of hcq

          -  concomitant use of other anti-malarial treatment or chemoprophylaxis

          -  history of retinopathy of any etiology

          -  psoriasis

          -  porphyria

          -  known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes
             < 1500) or thrombocytopenia (< 100 k)

          -  concomitant use of digoxin, cyclosporin, cimetidine, or tamoxifen

          -  known liver disease

          -  known long qt syndrome

          -  use of any investigational or non-registered drug or vaccine within 30 days preceding
             the first dose of the study drugs, or planned use during the study period
      


NCT04332107

        inclusion criteria:

          -  evidence of a positive sars-cov-2 test and test results received within the previous
             three days

          -  not currently hospitalized

          -  willing and able to receive study drug by mail

          -  willing and able to return the internet-based study questionnaires at baseline, day 3,
             7, 14, 21 days

          -  no known allergy or other contraindication to macrolides

          -  age 18 years or older at the time of enrollment

          -  no known history of prolongation of the qt interval (eg. history of torsades de
             pointes, congenital long qt syndrome, bradyarrhthmia)

          -  no recent use of hydroxychloroquine within the past 7 days for participants >55 years
             of age

          -  provision of informed consent
      


NCT04332991

        inclusion criteria:

          1. age ≥18 years

          2. currently hospitalized or in an emergency department with anticipated hospitalization.

          3. symptoms of acute respiratory infection, defined as one or more of the following:

               1. cough

               2. fever (> 37.5° c / 99.5° f)

               3. shortness of breath

               4. sore throat

          4. laboratory-confirmed sars-cov-2 infection within the past 10 days or sars-cov-2
             laboratory test result pending plus a high clinical suspicion for covid-19 as
             indicated by fulfilling all of the following:

               1. cough with duration ≤10 days

               2. bilateral pulmonary infiltrates on chest imaging (radiograph, or computed
                  tomography or ultrasound) or new hypoxemia defined as spo2 ≤94% on room air

               3. no alternative explanation for symptoms of acute respiratory infection

        exclusion criteria:

          1. prisoner

          2. pregnancy

          3. breast feeding

          4. symptoms of acute respiratory infection for >10 days before randomization

          5. >48 hours between meeting inclusion criteria and randomization

          6. seizure disorder

          7. porphyria cutanea tarda

          8. diagnosis of long qt syndrome

          9. qtc >500 ms on electrocardiogram within 72 hours prior to enrollment

         10. known allergy to hydroxychloroquine, chloroquine, or amodiaquine

         11. receipt in the 12 hours prior to enrollment, or planned administration during the
             5-day study period that treating clinicians feel cannot be substituted for another
             medication, of any of the following: amiodarone; cimetidine; dofetilide;
             phenobarbital; phenytoin; sotalol

         12. receipt of >1 dose of hydroxychloroquine or chloroquine in the 10 days prior to
             enrollment

         13. inability to receive enteral medications

         14. inability to be contacted on day 15 for clinical outcome assessment
      


NCT04333732

        inclusion criteria:

          1. age ≥18 years.

          2. healthcare worker based in a primary, secondary or tertiary healthcare setting with a
             high risk of developing covid-19 due to their potential exposure to patients with
             sars-cov-2 infection.

          3. must have a 'smart' mobile phone with access to the internet for data collection
             purposes.

          4. participants will provide informed consent via an electronic consent process.

        exclusion criteria:

          1. weight outside range 50 kg - 200 kg (110 lbs - 440 lbs).

          2. prior enrolment into this or other covid-19 prevention or treatment trials.

          3. self-reported, diagnosed infection with sars-cov-2 or previous covid-19 diagnosis
             within the last 6 months.

          4. self-reported current acute respiratory infection.

          5. concurrent and/or recent involvement in other research, or use of chloroquine;
             hydroxychloroquine or any other 4-aminoquinolone, or another experimental
             investigational medicinal product that is likely to interfere with the study
             medication within three months of study enrolment.

          6. antimalarial agents (lumefantrine, mefloquine, pyronaridine or amodiaquine), since
             they may cause a dangerous drug interaction.

          7. self-reported known allergies to the imp and excipients of imp and placebo.

          8. self-reported presence or history of the following conditions: retinopathy or retinal
             disease; cardiomyopathy; cardiac arrhythmia; known long qtc; psoriasis; porphyria
             cutanea tarda; epilepsy; myasthenia gravis; myopathy of any cause; serious hepatic or
             renal disease; severe depression; currently undergoing treatment for tuberculosis.

          9. self-reported current use of medication with known serious hepatotoxic effects or
             known interaction with chloroquine

         10. inability or unwillingness to be followed up for the trial period

        nb: pregnancy and breastfeeding are not exclusions for entry.
      


NCT04334382

        inclusion criteria:

          -  adult, age>44 years, competent to provide consent

          -  confirmed covid-19, via a positive nucleic acid assay for covid-19 within the last 7
             days

        exclusion criteria:

          -  participants already prescribed chloroquine, hydroxychloroquine, or azithromycin

          -  allergy to hydroxychloroquine or azithromycin

          -  history of bone marrow transplant

          -  known g6pd (glucose-6-phosphate dehydrogenase deficiency) deficiency

          -  chronic hemodialysis, peritoneal dialysis, continuous renal replacement therapy or
             glomerular filtration rate < 20ml/min/1.73m2

          -  liver disease (e.g. child pugh score ≥ b or ast (aspartate transaminase)>2 times upper
             limit)

          -  psoriasis

          -  porphyria

          -  known cardiac conduction delay (qtc > 500msec) or taking any prescription medications
             known to prolong qt interval

          -  concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone

          -  prisoner

          -  weight < 35kg

          -  inability to follow-up - no cell phone or no address or not spanish or english
             speaking

          -  receipt of any experimental treatment for sars-cov-2 (off-label, compassionate use, or
             trial related) within the 30 days prior to the time of the screening evaluation

          -  no symptoms attributable to covid-19

          -  pregnant or nursing
      


NCT04340232

        inclusion criteria:

          -  male or female aged 18 - 89 years at time of enrollment

          -  hospitalized (or documented plan to hospitalize if patient is in the emergency
             department) with symptoms suggestive of covid-19

          -  illness of any duration that meets each of the following:

               1. evidence of pneumonia, including radiographic infiltrates by imaging (chest
                  x-ray, ct scan, etc.) or clinical assessment (rales/crackles on exam)

               2. requires supportive care, including non-invasive supplemental oxygen

          -  laboratory-confirmed sars-cov-2 infection as determined by pcr or other commercial or
             public health assay within 7 days of enrollment

          -  understands and agrees to comply with planned study procedures

          -  provides informed consent signed by study patient or legally acceptable representative

        exclusion criteria:

          -  absolute lymphocyte count is less than 500 cells/mm

          -  absolute neutrophil count is less than 1000 cells/mm

          -  hemoglobin level is less than 8 g/dl

          -  estimated gfr is less than 60 ml/min/1.73 m2

          -  alt or ast is over 5 times the upper limit of normal

          -  treatment with other jak inhibitors, oat3 inhibitors, biologic disease-modifying
             anti-rheumatic drugs (dmards), anti-il-6 or anti-il-6r antibodies, or potent
             immunosuppressants such as azathioprine. and cyclosporine concurrently or within the
             past 5 days. note: recent or concurrent treatment with hydroxychloroquine or
             chloroquine is allowable, as these are 'non-biologic' dmards with potential antiviral
             activity.

          -  history of hiv infection and on active immunosuppressant therapy

          -  current hematological or solid organ malignancy and on active immunosuppressant
             therapy

          -  active tuberculosis (tb) infection or known or suspected systemic bacterial or fungal
             infection

          -  pregnancy or breast feeding

          -  known allergy to baricitinib

          -  in the opinion of the investigator, they are unlikely to survive for >48 hours from
             screening

          -  any physical examination findings and/or history of any illness that, in the opinion
             of the investigator, might confound the results of the study or pose an additional
             risk to the patient by their participation in the study

        additional exclusion criteria for phase 2 only:

        • invasive oxygen supplementation, including mechanical ventilation and extracorporeal
        membrane oxygenation (ecmo)
      


NCT04340557

        inclusion criteria:

          -  confirmed covid-19 positive test result

          -  mild to moderate respiratory disease defined by oxygen requirement of at least 2 l/min
             to maintain oxygen saturation level ≥92%.

          -  systolic blood pressure ≥ 110 mmhg.

          -  age ≥18 years old.

          -  access to an electronic device that is able to access docusign® online and email for
             consenting.

          -  able to read/write/speak english or spanish fluently.

          -  subjects must have the ability to understand the requirements of the study, provide
             informed consent, and provide authorization of use and disclosure of personal health
             information.

          -  negative pregnancy test for women of childbearing potential.

        exclusion criteria:

          -  severe allergy to any arb or ace-inhibitor, including angioedema

          -  in the intensive care unit at screening.

          -  home meds include any kind of ace inhibitor or arb

          -  sbp <110 mmhg

          -  acute kidney injury (50% reduction in gfr from baseline at admission to any time
             during treatment in the study treatment arm)

          -  hyperkalemia >5.0 mmol/l at baseline or any time during treatment in the study
             treatment arm

          -  creatinine clearance < 30 ml/min at baseline or any time during treatment in the study
             treatment arm
      


NCT04341441

        inclusion criteria:

          1. participant is willing and able to provide informed consent.

          2. participant is 18-75 years of age.

          3. participant does not have symptoms of respiratory infection, including cough, fevers
             (temperature >38.0c), difficulty breathing, shortness of breath, chest pains, malaise,
             myalgia, headaches, nausea or vomiting, or other symptoms associated with covid-19.

          4. participant is willing to provide blood samples for the study.

          5. subject agrees to all aspects of the study.

          6. the participant has no known allergies or contraindications (as stated in the consent
             form) to the use of hydroxychloroquine (hcq) as noted in the exclusion criteria and
             pharmacy sections.

        exclusion criteria:

          1. does not meet inclusion criteria.

          2. participant unable or unwilling to provide informed consent.

          3. participant has any of the symptoms above or screens positive for possible covid-19
             disease.

          4. participant is currently enrolled in a study to evaluate an investigational drug.

          5. vulnerable populations deemed inappropriate for study by the site principal
             investigator.

          6. the participant has a known allergy/hypersensitivity or has a medication or
             co-morbidity (including history of gastric bypass, epilepsy, cardiovascular disease or
             renal failure) that prevents the use of hcq (see pharmacy section).

          7. the participant is a woman of childbearing age whose pregnancy status is unknown and
             is not willing to use 2 methods of contraception.

          8. the participant is pregnant or nursing.

          9. the participant was diagnosed with retinopathy prior to study entry.

         10. the participant has a diagnosis of porphyria prior to study entry.

         11. the participant has renal failure with a creatinine clearance of <10 ml/min,
             pre-dialysis or requiring dialysis.

         12. the participant has a family history of sudden cardiac death.

         13. the participant is currently on diuretic therapy.

         14. the participant has a history of known prolonged qt syndrome.

         15. the participant is already taking any of the following medications: abiraterone
             acetate, agalsidase, amodiaquine, azithromycin, conivaptan, dabrafenib, dacomitinib,
             dapsone (systemic), digoxin, enzalutamide, fusidic acid (systemic), idelalisib,
             lanthanum, lumefantrine, mefloquine, mifepristone, mitotane, pimozide, qt-prolonging
             agents, stiripentol).
      


NCT04341727

        inclusion criteria:

          -  hospitalization for management of sars cov-2 infection

          -  positive sars cov-2 test

          -  age >=18 years

          -  provision of informed consent

          -  electrocardiogram (ecg) ≤48 hours prior to enrollment

          -  complete blood count, glucose-6 phosphate-dehydrogenase (g6pd), comprehensive
             metabolic panel and magnesium ≤48 hours prior to enrollment from standard of care.

          -  if participating in sexual activity that could lead to pregnancy, individuals of
             reproductive potential who can become pregnant must agree to use contraception
             throughout the study. at least one of the following must be used throughout the study:

               -  condom (male or female) with or without spermicide

               -  diaphragm or cervical cap with spermicide

               -  intrauterine device (iud)

               -  hormone-based contraceptive

        exclusion criteria:

          -  contraindication or allergy to chloroquine, hydroxychloroquine or azithromycin

          -  current use hydroxychloroquine, chloroquine or azithromycin

          -  concurrent use of another investigational agent

          -  invasive mechanical ventilation

          -  participants who have any severe and/or uncontrolled medical conditions such as:

               -  unstable angina pectoris,

               -  symptomatic congestive heart failure,

               -  myocardial infarction,

               -  cardiac arrhythmias or know prolonged qtc >470 males, >480 female on ecg

               -  pulmonary insufficiency,

               -  epilepsy (interaction with chloroquine),

          -  prior retinal eye disease

          -  concurrent malignancy requiring chemotherapy

          -  known chronic kidney disease, egfr<10 or dialysis

          -  g-6-pd deficiency, if unknown requires g6pd testing prior to enrollment

               -  known porphyria

               -  known myasthenia gravis

               -  currently pregnant or planning on getting pregnant while on study

               -  breast feeding

               -  ast/alt >five times the upper limit of normal uln*

               -  bilirubin >five times the uln*

               -  magnesium <1.4 meq/l*

               -  calcium <8.4mg/dl >10.6mg/dl*

               -  potassium <3.3 >5.5 meg/l*
      


NCT04341935

        inclusion criteria:

          -  type 2 diabetes mellitus (t2dm) as per american diabetes association (ada) guidelines

          -  age ≥ 18

          -  confirmed covid-19

          -  mild covid-19 defined as any of the following: fever, malaise, cough, headache, sore
             throat, myalgia, nasal congestion, diarrhea

          -  moderate covid-19 is defined as > 2 of the following in non-intubated patients: any
             symptom of mild disease, radiographic imaging (chest x-ray or lung ultrasound) with
             bilateral ground glass opacities or bilateral consolidations, spo2 <90% up to 5l nasal
             cannula (nc)

          -  no additional signs or symptoms of severe covid-19.

        exclusion criteria:

          -  type 1 diabetes mellitus (t1dm) diabetes, as per ada guidelines

          -  history of diabetic ketoacidosis (dka)

          -  history of acute pancreatitis

          -  chronic or acute renal failure with estimated glomerular filtration rate (egfr) < 30
             ml/min/1.73 m2

        exclusion criteria:

        t1dm diabetes, as per ada guidelines, history of dka, history of acute pancreatitis;
        chronic or acute renal failure with egfr < 30 ml/min/1.73 m2
      


NCT04344444

        inclusion criteria:

          -  age greater than 18 years

          -  positive sars-cov-2 testing or consistent clinical syndrome (based on clinical picture
             e.g. characteristic infiltrates on chest x-ray, laboratory findings, and with
             agreement by two physicians) in patients under investigation (puis).

          -  onset of symptoms < 7 days from date of enrollment

          -  oxygen saturation of >94% on room air with defined risk factors (table 1) consistent
             with moderate disease or oxygen saturation of < 94% on room air consistent with severe
             disease

          -  ability and willingness to comply with study procedures

        exclusion criteria:

          -  qtc greater than 450 milliseconds on screening ekg

          -  pregnant or lactating women

          -  inability to take oral pills or inability to use a feeding tube

          -  inability to obtain informed consent either from the patient or from the next of kin
             if patient is incapacitated. for the purpose of this study obtaining a verbal consent
             from a family member on the phone with a witness will be considered acceptable since
             there is a 'no visitor' policy in force at hospitals.

          -  patients requiring icu level care

          -  use of azithromycin or hydroxychloroquine within 30 days prior to admission
      


NCT04345692

        inclusion criteria:

        i. subject (or legally authorized representative) provides written informed consent prior
        to initiation of any study procedures.

        ii. understands and agrees to comply with planned study procedures. iii. male or female
        adult ≥18 - 95 years of age at time of enrolment. iv. laboratory-confirmed sars-cov-2
        infection in any specimen < 5 days prior to randomization.

        v. at least one of the following:

          1. radiographic infiltrates by imaging (chest x-ray, ct scan, etc.) or

          2. clinical assessment (evidence of rales/crackles on exam) and spo2 ≤94% on room air vi.
             women of childbearing potential must agree to use at least one primary form of
             contraception for the duration of the study.

        exclusion criteria:

        i. history of liver failure ii. history of stage 4 severe chronic kidney disease or
        requiring dialysis iii. self-reported pregnant or breast feeding. iv. allergy to
        hydroxychloroquine or choloroquine v. known contraindication to hydroxychloroquine,
        including retinopathy, g6pd deficiency, qt prolongation
      


NCT04346615

        inclusion criteria:

          1. written informed consent must be obtained from the subject in accordance with
             requirements of the study center's institutional review board (irb) or subjects must
             provide w informed consent in accordance with requirements of the study center's irb
             or ethics committee, prior to the initiation of any protocol-required procedures

          2. subjects must agree to provide all requested demographic information (i.e. gender,
             race)

          3. subjects must be able to read and understand english or spanish

          4. subjects must be over the age of 18 years

          5. subjects must have laboratory-confirmed sars-cov-2 infection as determined by
             pcr-based commercial or public health assay

          6. subjects must have symptoms that require hospitalization with supplemental oxygen as
             determined by the admitting physician. the maximum nasal cannula o2 concentration
             should be determined by the treating clinician and the limitations of the specific
             equipment

          7. subjects must be willing and able to comply with study-related procedures/assessments

        exclusion criteria:

          1. subjects in immediate need of mechanical ventilation or extracorporeal membrane
             oxygenation (ecmo)

          2. subjects with an estimated creatinine clearance of < 60 ml/min, at the screening visit

          3. prisoners or subjects who are involuntarily incarcerated

          4. subjects who are participating in any other investigational clinical trial while
             participating in this clinical trial

          5. subjects who are under the age of 18 years

          6. subjects who are pregnant (all potential female enrollees need to have a negative
             pregnancy test prior to ip administration)

          7. subjects with multi-organ failure

          8. subjects who have received more than 24 hours of supplemental oxygen prior to
             randomization

          9. subjects with prior significant pulmonary disease (e.g., copd/ild/chf/ipf) are
             excluded

         10. subjects receiving investigational therapies as part of a formal clinical trial for
             the treatment of covid-19. during the course of this study, investigational therapies
             that may become "standard of care" to treat covid-19, but are not part of a clinical
             trial, are allowed

         11. subjects who are on long-acting cgrp monoclonal antibodies will be excluded including
             aimovig (erenumab), emgality (galcanezumab), ajovy (fremanezumab), and vyepti
             (eptinezumab). additionally, the investigational oral cgrp receptor antagonist,
             atogepant, that is taken daily will also be excluded. oral cgrp receptor antagonists,
             nurtec odt (rimegepant) and ubelvy (ubrogepant) that are typically used prn
             infrequently will not be excluded as long the subject was not taking them on a daily
             basis and does not take them during the current study

         12. subjects who are unlikely to survive for more than 48 hours from the screening visit

         13. subjects with any of the following abnormal laboratory values at screening: aspartate
             ast or alt greater than 3x uln or bilirubin greater than 2x uln

         14. subjects with known active tb, history of incompletely treated tb, suspected or known
             extrapulmonary tb

         15. subjects with suspected or known systemic bacterial or fungal infections. however,
             empiric antibiotics are permitted.

         16. subjects who have participated in any clinical research study evaluating an ip or
             therapy within 3 months and less than 5 half-lives of ip prior to the screening visit

         17. subjects with any physical examination findings and/or history of any illness that, in
             the opinion of the study investigator, might confound the results of the study or pose
             an additional risk to the subject by their participation in the study
      


NCT04348370

        inclusion criteria:

          -  adult (≥18 years)

          -  male or female

          -  hospital personnel taking care for patients with known or suspected sars-cov-2
             infection and providing, on average, at least 25 hours per week of direct patient care

        exclusion criteria:

          -  known allergy to (components of) the bcg vaccine or serious adverse events to prior
             bcg administration

          -  known active or latent mycobacterium tuberculosis or with another mycobacterial
             species. a history with- or a suspicion of m. tuberculosis infection.

          -  fever (>38 c) within the past 24 hours

          -  age > 75 years

          -  pregnancy or planning pregnancy within 30 days of study enrollment

          -  breastfeeding

          -  suspicion of active viral or bacterial infection

          -  any immunocompromised subjects. this exclusion category comprises: a) subjects with
             known infection by the human immunodeficiency virus (hiv-1); b) subjects with known
             neutropenic with less than 1500 neutrophils/mm3; c) subjects with solid organ
             transplantation; d) subjects with bone marrow transplantation; e) subjects under
             chemotherapy; f) subjects with primary immunodeficiency; g) known severe lymphopenia
             with less than 400 lymphocytes/mm3; h) treatment with any anti-cytokine therapies. i)
             treatment with oral or intravenous steroids defined as daily doses of 10mg prednisone
             or equivalent for longer than 3 months

          -  living with someone who is immunosuppressed or taking immunosuppressive drugs

          -  previous documented infection with covid19

          -  active solid or non-solid malignancy or lymphoma within the prior two years

          -  direct involvement in the design or the execution of the study

          -  expected absence from work of ≥4 of the following 12 weeks due to any reason
             (holidays, maternity leave, retirement, planned surgery etc)

          -  not in possession of a smartphone

          -  inability to keep the vaccine site covered in the case of a draining pustule.
      


NCT04350593

        inclusion criteria:

          1. provision of informed consent

          2. male or female patients aged ≥18 years

          3. currently hospitalized

          4. confirmed sars-cov-2 infection by laboratory testing <72h prior to randomization or
             strongly suspected on presentation

          5. chest radiography or ct findings consistent with covid-19

          6. mild-moderate disease: spo2≥94% with low-flow supplemental oxygen (3 liters or less)

          7. medical history of at least one of the following:

               1. hypertension

               2. t2dm

               3. atherosclerotic cardiovascular disease

               4. heart failure (with either reduced or preserved lvef)

               5. ckd stage 3 to 4 (egfr between 25 to 60 ml/min/1.73 m2)

        key exclusion criteria:

          1. severe covid-19: requiring mechanical ventilation via endotracheal intubation, and/or
             non-invasive ventilation

          2. expected need for mechanical ventilation within the next 24 hours

          3. expected survival of less than 24 hours at the time of presentation

          4. egfr <25 ml/min/1.73 m2 or receiving renal replacement therapy/dialysis

          5. systolic bp <95 mmhg and/or requirement for vasopressor treatment and/or inotropic or
             mechanical circulatory support at screening

          6. history of type 1 diabetes mellitus

          7. currently receiving or has received in the last 14 days, experimental immune
             modulators and/or monoclonal antibody therapies for covid-19

          8. history of diabetic ketoacidosis within last 6 months

          9. current treatment with any sglt2i (eg, dapagliflozin, canagliflozin, empagliflozin,
             ertugliflozin) or having received treatment with any sglt2i within 4 weeks prior to
             screening

         10. current participation in another interventional clinical trial (with an
             investigational drug) that is not an observational registry

               -  note that use of rescue therapies including immune modulators, monoclonal
                  antibody therapies, antiviral therapies, and other agents that are approved or
                  being used through open label compassionate/expanded use programs or in
                  accordance with the local standard of care is permitted during the study.
      


NCT04352946

        inclusion criteria:

          1. health care worker (hcw) at the hospital who work on a "full time" basis during the
             study period. for the purposes of the study, "health care workers" are physicians,
             nurses, nurse practitioners, physician assistants, respiratory therapists, x-ray
             technicians, social workers and support staff (including but not limited to
             house-keeping, and porters).

          2. age ≥18 years.

          3. ability to communicate with study staff in english

        exclusion criteria:

          1. known hypersensitivity/allergy to hydroxychloroquine or to 4-aminoquinoline compounds.

          2. current use of hydroxychloroquine for the treatment of a medical condition.

          3. known prolonged qt syndrome, or concomitant medications which simultaneously may
             prolong the qtc that cannot be temporarily suspended/replaced. these are including but
             not limited to class ia, ic and iii antiarrhythmics; certain antidepressants,
             antipsychotics, and anti-infectives; domperidone; 5-hydroxytryptamine (5-ht)3 receptor
             antagonists; kinase inhibitors; histone deacetylase inhibitors beta-2 adrenoceptor
             agonists.

          4. known pre-existing retinopathy of the eye.

          5. disclosure of self-administered use of hydroxychloroquine or chloroquine currently
             under investigation <4 weeks prior to study. this window is intended to account for
             the drug half-life of hcq (21 days).

          6. baseline symptom of covid-19 disease at enrollment and baseline viral detection
             specimen positive for sars-cov-2. all participants with covid-19 symptoms at
             enrollment will be directed to have confirmatory testing (within the department or
             occupational health as per the site guidelines). participants who are negative for
             sars-cov-2 will be redirected to enrollment procedures, those testing positive will be
             excluded.
      


NCT04354428

        inclusion criteria:

          -  men or women 18 to 80 years of age, inclusive, at the time of signing the informed
             consent

          -  willing and able to provide informed consent

          -  laboratory confirmed sars-cov-2 infection, with test results within past 72 hours

          -  access to device and internet for telehealth visits

          -  at increased risk of developing severe covid-19 disease (at least one of the
             following)

               1. age ≥60 years

               2. presence of pulmonary disease, specifically moderate or severe persistent asthma,
                  chronic obstructive pulmonary disease, pulmonary hypertension, emphysema

               3. diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for
                  treatment

               4. hypertension, requiring at least 1 oral medication for treatment

               5. immunocompromised status due to disease (e.g., those living with human
                  immunodeficiency virus with a cd4 t-cell count of <200/mm3)

               6. immunocompromised status due to medication (e.g., persons taking 20 mg or more of
                  prednisone equivalents a day, anti-inflammatory monoclonal antibody therapies, or
                  cancer therapies)

               7. body mass index ≥30 (self-reported)

        exclusion criteria:

          -  known hypersensitivity to hcq or other 4-aminoquinoline compounds

          -  known hypersensitivity to azithromycin or other azalide or macrolide antibiotics

          -  currently hospitalized

          -  signs of respiratory distress prior to randomization, including respiratory rate >24

          -  current medications include hcq

          -  concomitant use of other anti-malarial treatment or chemoprophylaxis

          -  history of retinopathy of any etiology

          -  psoriasis

          -  porphyria

          -  chronic kidney disease (stage iv or receiving dialysis)

          -  known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes
             <1500) or thrombocytopenia (<100 k)

          -  concomitant use of digoxin, cyclosporin, cimetidine, amiodarone, or tamoxifen

          -  known cirrhosis

          -  known personal or family history of long qt syndrome

          -  history of coronary artery disease with a history of graft or stent

          -  history of heart failure, class 2 or greater using the new york heart association
             functional class

          -  taking medications associated with prolonged qt such as antipsychotic medications or
             antidepressants (e.g., citalopram, venlafaxine, and bupropion) and unable to stop
             during the trial

          -  taking warfarin (coumadin or jantoven)

          -  known history of glucose-6-phosphate-dehydrogenase deficiency

          -  history of myasthenia gravis
      


NCT04356937

        inclusion criteria:

        patients who meet all of the following criteria will be eligible to participate in the
        study:

          1. must have provided informed consent in a manner approved by the investigator's
             institutional review board (irb) or independent ethics committee (iec) prior to any
             assessments. if a patient is unable to provide informed consent due to their medical
             condition, the patient's legally authorized representative may consent on behalf of
             the study patient, as permitted by local law and institutional standard operating
             procedures;

          2. age > 18 and < 80 years old

          3. male or female gender

          4. confirmed sars-cov-2 infection by np swab pcr

          5. admitted to non-icu level care at mgh

          6. with evidence of severe covid-19 (at least 1 of the following):

               1. fever > 38c

               2. bilateral pulmonary infiltrates on chest x ray

               3. need for supplemental o2 to maintain saturation > 92%

          7. and at least 1 of the following:

               1. ferritin > 500 ng/ml

               2. crp > 50 mg/l

          8. women of childbearing potential (ie, not post-menopausal or surgically sterilized)
             must have a negative highly sensitive urine or serum pregnancy test before
             randomization. participating women of childbearing potential must be willing to
             consistently use effective methods of contraception (ie, condom, combined oral
             contraceptive, implant, injectable, indwelling intrauterine device, or a vasectomized
             partner) from screening until at least 90 days after administration of the last dose
             of study drug;

          9. the patient must be willing and able to provide informed consent and abide all study
             requirements and restrictions.

        exclusion criteria:

        patients who meet any of the following criteria will be excluded from participation in the
        study:

          1. unable to provide verbal informed consent

          2. uncontrolled bacterial, fungal, or non-covid viral infection

          3. active tb or ltbi with < 1 month of treatment

          4. any prior investigational immunologic therapy (for instance with biologic or jak
             inhibitor) within 28-days or 3 half-lives of the agent

          5. any concurrent immunosuppressive medication that the pi believes would put the patient
             at higher risk

          6. oral or iv corticosteroid for non-covid-19 indication within the last 7 days at a dose
             of ≥ 10 mg prednisone or equivalent per day

          7. history of diverticulitis or bowel perforation

          8. anc <500, platelets <50,000*

          9. ast/alt > 5x uln

         10. women who are pregnant or planning to get pregnant in the next 90 days;

         11. any condition that could interfere with, or for known allergy to the study drug or any
             of its ingredients or known allergy to any other anti il 6 agents;

         12. any condition that could interfere with or for which the treatment might interfere
             with, the conduct of the study or interpretation of the study results, or that would,
             in the opinion of the investigator, increase the risk of the participant by
             participating in the study.
      


NCT04359277

        inclusion criteria:

        in order to be eligible to participate in this study, an individual must meet all of the
        following criteria:

          1. >18 years of age

          2. hospitalized patient with a diagnosis of covid-19

          3. consistent with the institution guidelines, d-dimer > 500ng/ml

               1. if a d-dimer is between 500ng/ml to 2,000ng/ml - there appears to be clinical
                  equipoise by the nyu medical community

               2. if a d-dimer is >2,000 and < 10,000 and is not on a higher dose anticoagulation
                  and a blood clot is not suspected and there is clinical equipoise, a patient may
                  be approached for enrollment

        exclusion criteria:

        an individual who meets any of the following criteria will be excluded from participation
        in this study:

          1. meeting alternative indication for higher-dose anticoagulation

               1. prevalent blood clot at the time of enrollment

               2. on renal replacement therapies (crrt, cvvh)

               3. d-dimer >10,000 ng/ml

               4. change in d-dimer >6x over the admission lab value

               5. renal failure requiring renal replacement therapy

               6. prior vte

               7. atrial fibrillation (with a chads2 score >1) on oral anticoagulant therapy
                  already

          2. prior heparin induced thrombocytopenia within 100 days

          3. stroke within 30 days

          4. prior hemorrhagic stroke (ever)

          5. gi bleed within the past 6 months

          6. platelet count <100,000

          7. pregnancy

          8. anemia with a hemoglobin <9mg/dl

          9. signs of active bleeding (e.g. requirement of a blood transfusion in the past 30 days)

         10. other high bleeding risk (i.e. trauma, use of dual antiplatelet therapy)

         11. renal failure on admission (by rifle criteria 3x change in serum creatinine from
             baseline or >75% reduction in gfr or urine output <0.3ml/kg over 24 hours or anuria
             for 12 hours)

         12. subjects who have no capacity to consent for themselves.
      


NCT04361552

        inclusion criteria:

          -  diagnosis with sars-cov-2 by the currently available assays (food and drug
             administration [fda] approved)

          -  should be hospitalized and exhibit at least one of the following predictors of
             mortality

               -  age >= 65 years

               -  current smoker (smoked >= 100 cigarettes in life and actively smoking)

               -  chronic obstructive pulmonary disease (copd)

               -  diabetes

               -  hypertension

               -  coronary artery disease

               -  cerebrovascular accident (cva)

               -  chronic renal disease (creatinine of >= 2 mg/dl)

               -  cancer

               -  patients that have c-reactive protein (crp) >= 10 mg/l

               -  d-dimer >= 0.5 mg/l

               -  procalcitonin >= 0.5 mg/l

               -  lactate dehydrogenase (ldh) >= upper limit of normal (uln)

          -  patients or authorized family member willing to sign informed consent to participate
             in this study

        exclusion criteria:

          -  pregnant or lactating women

          -  hypersensitivity to tocilizumab

          -  patients or authorized family member unwilling to sign informed consent to participate
             in this study

          -  uncontrolled tuberculosis, or any uncontrolled fungal infection (eg: candidemia)
      


NCT04362176

        inclusion criteria:

          -  age ≥18 years

          -  currently hospitalized or in an emergency department with anticipated hospitalization.

          -  symptoms of acute respiratory infection, defined as one or more of the following:
             cough, fever (> 37.5° c / 99.5° f), shortness of breath

          -  laboratory-confirmed sars-cov-2 infection within the past 10 days

        exclusion criteria:

          -  prisoner

          -  unable to randomize within 14 days after onset of acute respiratory infection symptoms

          -  unable to randomize within 48 hours after hospital arrival

          -  inability to be contacted on day 29-36 for clinical outcome assessment

          -  receipt of pooled immunoglobulin in the past 30 days

          -  contraindications to transfusion or history of prior reactions to transfusion blood
             products

          -  previous enrollment in this trial
      


NCT04363866

        inclusion criteria:

          1. ability to understand and the willingness to sign a written informed consent document.

          2. individuals aged ≥ 18 years of all races and ethnic groups.

          3. must have documented positive test result for sars-cov-2 (covid19), or high clinical
             suspicion for sars-cov-2 based on presence of typical clinical findings (e.g., fever,
             respiratory symptoms, pulmonary abnormalities on chest x-ray or ct scan), lack of
             alternative diagnosis, and history of exposure to a known case of sars-cov-2 infection
             within the past 14 days

          4. not receiving institutional therapy for treatment of sars-cov-2, including (but not
             limited to) remdesivir, chloroquine, hydroxychloroquine, or any other investigational
             agent(s).

          5. must meet at least one of the following clinical stratifications:

               1. have at least 1 minor criterion per ats criteria (refer to appendix a), or

               2. have fever, respiratory symptoms, with pneumonia visible on chest imaging (e.g.,
                  x-ray or computed tomography [ct]), or

               3. high risk for poor outcome, as defined by any one of the following:

             i. age ≥ 60 years old

             ii. underlying medical comorbidities, defined as:

               -  cardiovascular disease

               -  diabetes

               -  chronic respiratory disease (e.g., copd)

               -  hypertension, defined as blood pressure ≥ 140 / 90 mmhg

             iii. solid organ or stem cell transplant recipient

             iv. diagnosis of solid or hematologic malignancy being treated with systemic
             chemotherapy

             v. receipt of biologic agent or prednisone > 0.5 mg/kg/day (or equivalent)

          6. participants with preexisting auditory damage are allowed.

          7. participants with a history of epilepsy are allowed.

          8. female participants of childbearing potential (focbp) must have a negative serum or
             urine pregnancy test (per institutional standards) prior to the start of study drug.

          9. focbp must agree to use highly-effective method(s) of contraception during the study
             and for 1 months after the last dose of study drug. focbp are those who have not been
             surgically sterilized or have not been free from menses for >1 year without an
             alternative medical cause.

         10. male participants must agree to use an adequate method of contraception starting with
             the first dose of study therapy through at least 1 months after the last dose of study
             drug.

         11. participant must agree to not breastfeed during the study or for 30 days after the
             last dose of study treatment.

        exclusion criteria:

          1. the patient has serious and/or uncontrolled preexisting medical condition(s) that, in
             the judgment of the investigator, would preclude participation in this study.

          2. judgment by the investigator that the patient should not participate in the study if
             the patient is unlikely to comply with study procedures, restrictions and
             requirements.

          3. psychiatric illness/social situations, or any condition that, in the opinion of the
             investigator, would interfere with evaluation of study treatment or interpretation of
             participant safety or study results, or substantially increase risk of incurring aes,
             or compromise the ability of the patient to give written informed consent.

          4. resting ecg indicating uncontrolled, potentially reversible cardiac conditions, as
             judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic
             arrhythmia, congestive heart failure, qtcf prolongation >500 ms, electrolyte
             disturbances, etc.), or participants with congenital long qt syndrome

          5. patients with myesthenia gravis or other neuromuscular disorders

          6. patients with history of psoriasis.

             a. may be waived at the discretion of the pi

          7. patients with history of porphyria

             a. may be waived at the discretion of the pi

          8. concomitant use of other antiviral agents for the study's duration, but may be waived
             at discretion of the principal investigator

          9. hypersensitivity to the study agent, or any of its excipients.

         10. females who are pregnant or lactating.
      


